Loading organizations...
§ Private Profile · Hangzhou, Zhejiang, China
Zewei Biotech focuses on the research, development, production, and sales of super-biocompatible materials—zwitterionic polymers
Nanjing Zewei Biotechnology Co., Ltd., operating as Zewei Biotech, specializes in the research, development, production, and sales of super-biocompatible materials. The company's core technological emphasis is on zwitterionic polymers, which are a class of advanced materials engineered for optimal interaction within biological environments. These specialized polymers are designed to offer enhanced compatibility and performance in applications that require direct contact with living systems.
Zewei Biotech's focus on these advanced materials positions it within the biotechnology sector, addressing the demand for innovative solutions in areas where the material-biological interface is critical. By developing materials that minimize adverse reactions and integrate effectively, the company aims to contribute to advancements in various biological and medical applications.
Zewei Biotech specializes in the research, development, production, and sales of super-biocompatible materials, with a core focus on zwitterionic polymers.
Zewei Biotech, officially Nanjing Zewei Biotechnology Co., Ltd., is headquartered in Nanjing, China.
Zewei Biotech specializes in the research, development, production, and sales of super-biocompatible materials, with a core focus on zwitterionic polymers.
Zewei Biotech, officially Nanjing Zewei Biotechnology Co., Ltd., is headquartered in Nanjing, China.
Nanjing Zewei Biotechnology Co., Ltd., known as Zewei Biotech, is a company dedicated to the field of advanced biomaterials. Its primary business encompasses the research, development, production, and sales of super-biocompatible materials, with a particular specialization in zwitterionic polymers. These materials are distinguished by their ability to interact favorably with biological systems, minimizing undesirable reactions and enhancing performance in sensitive applications.
The company's scientific efforts are concentrated on harnessing the unique properties of zwitterionic polymer technology. This involves extensive research into their synthesis, characterization, and application potential across various biological contexts. The goal is to create materials that not only meet stringent biocompatibility requirements but also offer superior functional attributes for integration into complex biological systems.
Zewei Biotech's operational model covers the full spectrum from initial scientific discovery to market delivery. This integrated approach ensures that the quality and specific characteristics of its super-biocompatible products are maintained throughout their lifecycle. The company's commitment to this specialized area of material science underscores its role in supporting innovation within the broader biotechnology and medical device industries.
While the specific end-use applications of their zwitterionic polymers are diverse, the company's official website alludes to complex biological challenges, including discussions around cancer. This suggests an interest in contributing to fields where advanced material science can offer new avenues for understanding, diagnosis, or treatment strategies. Zewei Biotech maintains its headquarters in Nanjing, China.
Zewei Biotech most recently raised Seed in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 9, 2026 | Seed | Zhejiang University Qizhen Venture Capital | — | Announced |